Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Paolo Regi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7639-039X; OpenAlex author ID A5018561366. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
44
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 12

  1. The Role of a "Conservative" Resection Strategy After Neoadjuvant Treatment for Borderline/Locally Advanced PDAC with Arterial Involvement: A Single-Centre Ret… Co-author DOI 10.3390/cancers18050830↗
  2. Bayesan Model to Predict R Status After Neoadjuvant Therapy in Pancreatic Cancer. Co-author DOI 10.3390/cancers16234106↗
  3. Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.02.005↗
  4. Prognostic Factors After Pancreatectomy for Pancreatic Cancer Initially Metastatic to the Liver. Co-author DOI 10.1245/s10434-022-12385-4↗
  5. Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial. Co-author DOI 10.1016/j.pan.2021.06.005↗
  6. A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial. Co-author DOI 10.1177/1758835920947969↗
  7. FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules. Co-author DOI 10.1177/1758835920947970↗
  8. Technique, safety, and feasibility of EUS-guided radiofrequency ablation in unresectable pancreatic cancer. Co-author DOI 10.1007/s00464-018-6217-x↗
  9. Immunomodulation after radiofrequency ablation of locally advanced pancreatic cancer by monitoring the immune response in 10 patients. Co-author DOI 10.1016/j.pan.2017.09.008↗
  10. Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery? First author DOI 10.1245/s10434-017-5885-4↗
  11. Short term chemotherapy followed by radiofrequency ablation in stage III pancreatic cancer: results from a single center. Co-author DOI 10.1007/s00534-013-0613-3↗
  12. Clinicopathological features of adenosquamous pancreatic cancer. Co-author DOI 10.1007/s00423-010-0677-3↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Isabella M. Frigerio · 11 shared papers, 2013–2026 · strength 1.23
  2. Giovanni Butturini · 11 shared papers, 2011–2026 · strength 1.22
  3. Alessandro Giardino · 10 shared papers, 2013–2026 · strength 1.15
  4. Filippo Scopelliti · 9 shared papers, 2017–2026 · strength 1.10
  5. Roberto Girelli · 9 shared papers, 2013–2026 · strength 1.07
  6. Claudio Bassi · 7 shared papers, 2011–2022 · strength 0.50
  7. Giuseppe Malleo · 5 shared papers, 2011–2022 · strength 0.40
  8. Gaya Spolverato · 2 shared papers, 2023–2024 · strength 0.35
  9. Quoc Riccardo Bao · 2 shared papers, 2023–2024 · strength 0.35
  10. Roberto Salvia · 4 shared papers, 2013–2022 · strength 0.35
  11. Paolo Pederzoli · 2 shared papers, 2018–2026 · strength 0.33
  12. Mirko D’Onofrio · 4 shared papers, 2011–2021 · strength 0.26
  13. Erica Pizzocaro · 1 shared paper, 2026 · strength 0.25
  14. Roberta Vella · 1 shared paper, 2026 · strength 0.25
  15. Salvatore Paiella · 3 shared papers, 2017–2021 · strength 0.23
  16. Alessandro Esposito · 2 shared papers, 2020–2022 · strength 0.21
  17. Darío Gregori · 1 shared paper, 2024 · strength 0.19
  18. Roberto Bianco · 2 shared papers, 2020–2021 · strength 0.18
  19. Michèle Milella · 2 shared papers, 2020–2021 · strength 0.17
  20. Marzia Tripepi · 1 shared paper, 2023 · strength 0.16
  21. Matteo De Pastena · 1 shared paper, 2022 · strength 0.13
  22. Paola Capelli · 2 shared papers, 2017–2020 · strength 0.13
  23. Andrea Mambrini · 1 shared paper, 2021 · strength 0.10
  24. Maurizio Cantore · 1 shared paper, 2021 · strength 0.10
  25. Giammaria Fiorentini · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.